Cite
HARVARD Citation
Papadopoulos, K. et al. (2015). A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].